Pharm'Up 
A recent study led by researchers at the Icahn School of Medicine at Mount Sinai has found a promising new approach to treating advanced triple-negative breast cancer (TNBC). The research, published in Breast Cancer Research and Treatment, shows that adding the targeted therapy everolimus to standard carboplatin chemotherapy significantly slows disease progression, offering a potential new treatment option for patients facing this aggressive form of cancer.
Trial Design and Key Findings
The randomized phase 2 clinical trial focused on patients whose advanced TNBC had already been treated up to three times. The study compared the efficacy and safety of carboplatin alone versus the combination of carboplatin and everolimus.
The results were a significant step forward:
- Extended Progression-Free Survival: Patients who received the combination therapy saw a 52% reduction in the risk of their disease progressing or of death. This means they lived longer without their cancer getting worse compared to those on carboplatin alone.
- Favorable Safety Profile: The regimen was well tolerated, with no unexpected or major safety concerns reported.
“Triple-negative breast cancer has limited treatment options and is often resistant to standard therapies,” said Dr. Amy Tiersten, senior author of the study. “Our findings suggest that the combination of carboplatin and everolimus could offer a new option for patients, and should be further tested in larger clinical trials to confirm its effectiveness and safety.”
Understanding the Mechanism
TNBC is a particularly challenging cancer because it lacks the three key receptors (estrogen, progesterone, and HER2) that are often targeted by other breast cancer treatments. Many TNBC tumors also lack the PTEN gene, a crucial tumor suppressor. Without PTEN, a cellular “growth switch” called the mTOR pathway becomes overactive, driving rapid cancer growth.
This is where the combination therapy shows its promise. While carboplatin is a common chemotherapy that kills fast-growing cancer cells, everolimus specifically targets and blocks the overactive mTOR pathway. By attacking the cancer from two different angles—disrupting both cell growth and its underlying signaling mechanism—the combination therapy appears to be more effective than a single treatment alone.
The Path Forward
While the phase 2 trial results are highly encouraging, the researchers and authors of the study emphasize the need for larger phase 3 clinical trials to confirm the findings. If validated in these larger studies, the carboplatin and everolimus combination could become a crucial new treatment option for patients with advanced TNBC, particularly as an alternative to single-agent chemotherapy.
About the Author
